PharmacoEconomics

, Volume 25, Issue 6, pp 511–521 | Cite as

Costs and Benefits of Direct-to-Consumer Advertising

The Case of Depression
Original Research Article

Abstract

Background

Direct-to-consumer advertising (DTCA) is legal in the US and New Zealand, but illegal in the rest of the world. Little or no research exists on the social welfare implications of DTCA.

Aim

To quantify the total costs and benefits associated with both appropriate and inappropriate care due to DTCA, for the case of depression.

Methods

A cost-benefit model was developed using parameter estimates from available survey, epidemiological and experimental data. The model estimates the total benefits and costs (year 2002 values) of new appropriate and inappropriate care stimulated by DTCA for depression. Uncertainty in model parameters is addressed with sensitivity analyses.

Results

This study provides evidence that 94% of new antidepressant use due to DTCA is from non-depressed individuals. However, the average health benefit to each new depressed user is 63-fold greater than the cost per treatment, creating a positive overall social welfare effect; a net benefit of >$US72 million.

Conclusion

This analysis suggests that DTCA may lead to antidepressant treatment in 15-fold as many non-depressed people as depressed people. However, the costs of treating non-depressed people may be vastly outweighed by the much larger benefit accruing to treated depressed individuals. The cost-benefit ratio can be improved through better targeting of advertisements and higher quality treatment of depression.

Keywords

Paroxetine Physician Visit Antidepressant Treatment Depressed Individual Adjustment Disorder 

Notes

Acknowledgements

The author thanks Meredith Rosenthal, Joe Newhouse and David Cutler for their support and comments. In addition, thanks to Heidi Williams, Daniel Richenthal, Rena Conti and Erin Strumpf for providing comments on early drafts.

No sources of funding were used to assist in the preparation of this study. The author has no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Harder B. Pushing drugs. Science News July 30 2005; 168 (5): 75 [online]. Available from URL: http://www.sciencenews.org/articles/20050730/bob10.asp [Accessed 2007 May 2]CrossRefGoogle Scholar
  2. 2.
    Rosenthal M, Berndt E, Donahue J, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346 (7): 498–505PubMedCrossRefGoogle Scholar
  3. 3.
    Spence MM, Teleki SS, Cheetham TC, et al. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005 Oct; 62 (5): 544–559PubMedCrossRefGoogle Scholar
  4. 4.
    Galbraith JK. The affluent society. Boston (MA): Houghton-Mifflin Company, 1958: 155–156Google Scholar
  5. 5.
    Becker G, Murphy K. A simple theory of advertising as a good or bad. Q J Econ 1993; 108 (4): 941–964CrossRefGoogle Scholar
  6. 6.
    Iizuka T, Jin GZ. The effect of prescription drug advertising on doctors visits. J Econ Manag Strategy Sept 2005; 14 (3): 701–727CrossRefGoogle Scholar
  7. 7.
    Donahue J, Berndt E. Effects of direct-to-consumer advertising on medication choice: the case of antidepressants. J Public Policy Marketing 2004; 23 (2): 115–127CrossRefGoogle Scholar
  8. 8.
    Widespread belief that antidepressants are prescribed too often, particularly for teens and children. WSJOnline June 2004; 3 (12) [online]. Available from URL: http://www.harrisinteract ive.com/news/newsletters/wsjhealthnews/WSJOnline_HI_Health-CarePoll2004vol3_iss12.pdf [Accessed 2006 Nov 14]Google Scholar
  9. 9.
    Rosenthal MB, Berndt ER, Donohue JM, et al. Demand effects of recent changes in prescription drug promotion.In: Cutler DM, Garber AM, editors. Frontiers in health policy research. Vol. 6. Cambridge (MA): MIT Press, 2003Google Scholar
  10. 10.
    Weissman JS, Blumenthal D, Silk AJ, et al. Consumers’ reports on the health effects of direct-to-consumer drug advertising. Health Aff (Millwood 2003; web suppl: W3-82-95Google Scholar
  11. 11.
    Kessler R, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. JAMA 2003; 289: 3095–3105PubMedCrossRefGoogle Scholar
  12. 12.
    Kravitz R, Epstein R, Feldman M, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants. JAMA 2005; 293: 1995–2002PubMedCrossRefGoogle Scholar
  13. 13.
    Slaughter E. Consumer reaction to DTC advertising of prescription medicines 1997 to 2002. FDA presentation, 2003 Sep 25 [online]. Available from URL: http://www.fda.gov/cder/ ddmac/P1Slaughter/index.htm [Accessed 2006 Mar 23]Google Scholar
  14. 14.
    National Ambulatory Medical Care Survey: 2000 Summary Number 328. Washington, DC: National Center for Health Statistics, 2002 Jun 5Google Scholar
  15. 15.
    About.com. US Gov Info/Resources [online]. Available from URL: http://usgovinfo.about.com/cs/censusstatistic/a/latestpo pcounts.htm [Accessed 2007 May 3]Google Scholar
  16. 16.
    The Henry J. Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. Menlo Park (CA): The Henry J. Kaiser Family Foundation, November 2001 [online]. Available from URL: http://www.kff.org/rxdrugs/upload/Understanding-the-Effects-of-Direct-to-Consumer-Prescription-Drug-Advertising-Report.pdf [Accessed 2007 May 14]Google Scholar
  17. 17.
    Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286 (23): 2947–2955PubMedCrossRefGoogle Scholar
  18. 18.
    Young AS, Klap R, Sherbourne CD, et al. The quality of care of depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58 (1): 55–61PubMedCrossRefGoogle Scholar
  19. 19.
    Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs 2006; 20 (8): 623–632PubMedCrossRefGoogle Scholar
  20. 20.
    US Food and Drug Administration, Center for Drug Evaluation and Research. Aiken KJ. Direct-to-consumer advertising of prescription drugs: physician survey preliminary results [online]. Available from URL: http://www.fda.gov/cder/ddmac/globalsummit2003 [Accessed 2006 May 1]Google Scholar
  21. 21.
    Nurnberg HG, Hensley PL, Thompson PM, et al. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv 1999; 50 (10): 1351–1353PubMedGoogle Scholar
  22. 22.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28–40PubMedCrossRefGoogle Scholar
  23. 23.
    Frank RG, McGuire TG, Normand SL, et al. The value of mental health care at the system level: the case of treating depression. Health Aff (Millwood) 1999; 18 (5): 71–88CrossRefGoogle Scholar
  24. 24.
    Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132 (9): 743–756PubMedGoogle Scholar
  25. 25.
    Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998; 7 (5): 443–449PubMedCrossRefGoogle Scholar
  26. 26.
    Cutler, DM. Your money or your life. New York (NY): Oxford University Press, 2004Google Scholar
  27. 27.
    Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 2004; 42 (12): 1176–1185PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Harvard PhD Program in Health PolicyHarvard UniversityCambridgeUSA

Personalised recommendations